Feasibility of comprehensive genotyping specimens from radial endobronchial ultrasonography and electromagnetic navigation bronchoscopy.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
15
12
2020
accepted:
12
05
2021
entrez:
22
7
2021
pubmed:
23
7
2021
medline:
23
7
2021
Statut:
epublish
Résumé
Mini-invasive bronchoscopic techniques (such as radial endobronchial ultrasonography (rEBUS) and electromagnetic navigation (EMN)) have been developed to reach the peripheral lung but result in small samples. The feasibility of an adequate molecular testing from these specimens has been very little studied. We retrospectively reviewed EMN and rEBUS procedures performed in patients diagnosed with lung cancer in our institution in 2017 and 2018. We analysed the sensitivity for rEBUS and EMN and each sampling method, and the feasibility of a comprehensive molecular testing. In total, 317 rEBUS and 14 EMN were performed. Median sizes of tumours were 16 and 32 mm for EMN and rEBUS, respectively. Overall sensitivity for rEBUS and EMN was 84.3%. Cytology was found to be complementary with biopsies, with 13.3% of cancer diagnosed on cytology while biopsies were negative. Complication rate was 2.4% (pneumothorax 1.5%, mild haemoptysis 0.9%). Genotyping (immunohistochemistry for rEBUS and EMN are sensitive and safe procedures that result in limited samples, often not suitable for genotyping, highlighting the importance of integrating liquid biopsy in routine testing.
Identifiants
pubmed: 34291111
doi: 10.1183/23120541.00942-2020
pii: 00942-2020
pmc: PMC8287134
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2021.
Déclaration de conflit d'intérêts
Conflict of interest: M. Robin has nothing to disclose. Conflict of interest: L. Mhanna has nothing to disclose. Conflict of interest: L. Chaltiel has nothing to disclose. Conflict of interest: G. Plat has nothing to disclose. Conflict of interest: V. Héluain has nothing to disclose. Conflict of interest: C. Basset has nothing to disclose. Conflict of interest: J. Meilleroux has nothing to disclose. Conflict of interest: T. Filleron has nothing to disclose. Conflict of interest: J. Mazières has nothing to disclose. Conflict of interest: C. Hermant has nothing to disclose. Conflict of interest: N. Guibert has nothing to disclose.
Références
ERJ Open Res. 2019 Oct 21;5(4):
pubmed: 31649952
Respirology. 2017 Apr;22(3):443-453
pubmed: 28177181
Sci Rep. 2018 Apr 11;8(1):5837
pubmed: 29643378
Cells. 2020 Nov 16;9(11):
pubmed: 33207539
Rev Mal Respir. 2013 May;30(5):351-6
pubmed: 23746811
Cancer Cytopathol. 2013 Oct;121(10):552-60
pubmed: 23780873
Respirology. 2016 May;21(4):718-26
pubmed: 27099101
Am J Respir Crit Care Med. 2016 Jan 1;193(1):68-77
pubmed: 26367186
Ann Oncol. 2016 Jan;27(1):147-53
pubmed: 26483045
Eur Respir J. 2017 Apr 5;49(4):
pubmed: 28381431
Chest. 2009 Jul;136(1):229-236
pubmed: 18812446
Chest. 2018 Oct;154(4):827-837
pubmed: 30059678
Respirology. 2020 Sep;25(9):944-952
pubmed: 32643221
BMC Cancer. 2019 Jun 7;19(1):546
pubmed: 31174496
Respir Med. 2011 Nov;105(11):1704-11
pubmed: 21875783
Respirology. 2020 Sep;25(9):933-943
pubmed: 32335992
PLoS One. 2018 Jan 22;13(1):e0191590
pubmed: 29357388
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Eur Respir Rev. 2020 Feb 12;29(155):
pubmed: 32051167
Am J Pathol. 2002 Feb;160(2):449-57
pubmed: 11839565
Ann Oncol. 2018 Apr 1;29(4):1049-1055
pubmed: 29325035
N Engl J Med. 2020 Feb 6;382(6):503-513
pubmed: 31995683
Lung Cancer. 2018 Aug;122:72-75
pubmed: 30032849
Respirol Case Rep. 2017 Dec 22;6(2):e00287
pubmed: 29321931
Ann Thorac Surg. 2017 Feb;103(2):470-475
pubmed: 27825686
Tuberc Respir Dis (Seoul). 2019 Oct;82(4):319-327
pubmed: 31172704
J Thorac Dis. 2016 Sep;8(9):2551-2555
pubmed: 27747008